EGFR and non-small cell lung carcinoma: For instance, EGFR inhibitors, including erlotinib and gefitinib, have significantly improved outcomes in non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (Roskoski, 2023).